Kypha

About Kypha

Kypha, Inc. operates as a medical diagnostics company focused on developing in-vitro diagnostic biomarker tests to monitor immune system activity. Founded in 2010 by Paul Olson, the company is headquartered in St. Louis, Missouri. Paul Olson's background includes a co-founder and CSO role at Potentia Pharmaceuticals, where he contributed to the development of a complement inhibitor for age-related macular degeneration, and research positions at Harvard and Merck. The current President and CEO is Chad Stiening, who has a Ph.D. in life sciences and a background in technology commercialization with companies like Monsanto.

The company targets clinical laboratories, healthcare providers, and pharmaceutical companies, offering solutions to improve therapeutic development and clinical care for patients with immune-related conditions. Kypha's business model involves developing and commercializing specialized biomarker testing platforms and providing contract assay development and manufacturing services. Revenue is generated through the sale of its testing platforms and services to partners in the biopharma and clinical sectors. A significant milestone was the acquisition of Biosensia, an Irish diagnostics platform company, in July 2018. This acquisition brought Biosensia's RapiPlex platform and ISO 13485-certified manufacturing facilities in Dublin under Kypha's control, enhancing its product development and manufacturing capabilities.

Kypha's product portfolio is centered on providing precise, real-time information on complement proteins and other highly-labile proteins like cytokines. The flagship products include the Comp ACT® system and the RapiPlex™ system. The Comp ACT® is a portable, single-analyte system that delivers quantitative results from a small sample volume of various biological fluids, including blood, urine, or ocular fluid. The RapiPlex™ system, acquired through Biosensia, is a multiplex platform capable of performing up to 24 quantitative or qualitative measurements simultaneously from a single biological sample within 30 minutes. These platforms are designed for use in diverse settings, from point-of-care to centralized labs, enabling the monitoring of inflammatory and autoimmune diseases by analyzing biomarkers. The company also offers custom panel development and exploratory biomarker services to support bioanalytical and companion diagnostic needs for its partners.